Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006) in Healthy Adult Participants

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Dec 2024 Planned initiation date changed from 1 Aug 2024 to 1 Aug 2025.
06 Mar 2024 New trial record
12 Jan 2024 According to an InnoRNA media release, the company announced that its first-in-class bivalent Respiratory Syncytial Virus (RSV) mRNA Vaccine has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance to initiate a Phase I clinical trial. This is Innornas third IND approval granted by the FDA.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com